By Diana Novak Jones Jan 16 (Reuters) - The U.S. Supreme Court agreed on Friday to hear Bayer's bid to sharply limit lawsuits claiming that the company's Roundup weedkiller causes cancer and
US Supreme Court to Review Bayer's Appeal on Roundup Lawsuits
Bayer's Legal Challenges and Supreme Court Involvement
By Diana Novak Jones
Background of the Roundup Lawsuits
Jan 16 (Reuters) - The U.S. Supreme Court agreed on Friday to hear Bayer's bid to sharply limit lawsuits claiming that the company's Roundup weedkiller causes cancer and potentially avert billions of dollars in damages.
Arguments Presented by Bayer
The justices took up Bayer's appeal of a lower court's ruling in a case brought by a man who said he was diagnosed with non-Hodgkin's lymphoma after years of exposure to Roundup.
Impact of EPA Findings on Litigation
The Missouri Court of Appeals rejected the German pharmaceutical and biotechnology company's contention that federal law governing pesticides bars lawsuits making claims over pesticides under state laws.
Potential Consequences for Bayer
Bayer is facing similar claims from approximately 65,000 plaintiffs in U.S. state and federal courts. Roundup is among the most widely used weedkillers in the United States.
President Donald Trump's administration in December urged the Supreme Court to take up Bayer's appeal. In a brief filed at the court, U.S. Solicitor General D. John Sauer offered the administration's view that Bayer is correct in its reading of the law at issue.
Bayer is arguing that consumers should not be able to sue it under state law for failing to warn that Roundup increases cancer risk because the U.S. Environmental Protection Agency has found no such risk and requires no such warning. Bayer argued that federal law does not allow it to add any warning to the product beyond the EPA-approved label.
The company has made the U.S. Supreme Court a key part of its strategy to manage the claims, as a ruling that federal law preempts claims brought under state law would shut down the vast majority of the lawsuits. Monsanto said different courts have come down on opposite sides of the issue.
In the case of plaintiff John Durnell, the Missouri Court of Appeals upheld a $1.25 million verdict that a St. Louis jury awarded him over his cancer diagnosis.
Lawyers for Durnell had asked the Supreme Court to turn away Bayer's appeal. They said Durnell relied on Bayer's advertising and not just the label when he chose to use Roundup, and the company's marketing failed to warn consumers of the product's risks.
The company has paid about $10 billion to settle most of the Roundup lawsuits that were pending as of 2020, but failed to get a settlement covering future cases. New lawsuits have continued to pour in since then. Plaintiffs have said they developed non-Hodgkin's lymphoma and other forms of cancer due to using Roundup, either at home or on the job.
Bayer, which acquired Roundup as part of its $63 billion purchase of agrochemical company Monsanto in 2018, has said that decades of studies have shown Roundup and its active ingredient, glyphosate, are safe for human use.
"EPA has repeatedly determined that glyphosate is not likely to be carcinogenic in humans, and the agency has repeatedly approved Roundup labels that did not contain cancer warnings," Sauer said in the administration's brief to the Supreme Court.
The company has had a mixed record at trial in the Roundup lawsuits. Bayer has prevailed in a series of Roundup trials, but it was also hit with large jury awards in the past few years, including a $2.1 billion verdict in a case in the U.S. state of Georgia in 2025.
Bayer has asked the Supreme Court to consider the Roundup litigation before, but was rebuffed in 2022. Since then, one federal appeals court agreed with the company in a split from other appeals courts.
Bayer has threatened to withdraw Roundup from the U.S. market as it fights the litigation. The company replaced glyphosate in U.S. consumer products with different weed-killing substances.
(Reporting by Diana Novak Jones in Chicago; Additional reporting by Andrew Chung; Editing by Will Dunham)
